Missing cosentyx?

What are the alternatives if Cosentyx is missing from the market?

Cosentyx, also known as secukinumab, is a biologic drug used to treat psoriatic arthritis and plaque psoriasis [1]. In some cases, it may be missing from the market due to various reasons such as manufacturing issues or supply chain disruptions.

How does the shortage impact patients?

The shortage of Cosentyx may lead to significant disruptions in patient care and treatment plans. Patients who are reliant on the drug may need to explore alternative treatments to manage their symptoms. However, it's essential to note that not all biologics are suitable for everyone, and switching to an alternative treatment may require a consultation with a healthcare professional to determine the best course of action [2].

Is there a list of alternative biologics available?

Yes, there are several alternative biologics available that may be used to treat psoriatic arthritis and plaque psoriasis. Some of the commonly used alternatives include Enbrel (etanercept), Humira (adalimumab), and Stelara (ustekinumab) [3]. It's essential to consult with a healthcare professional to determine the most suitable alternative based on individual patient needs and medical history.

When will Cosentyx be back in stock?

The duration of the Cosentyx shortage can vary depending on several factors, including the severity of the shortage and the efforts of the manufacturer to resolve the issue. In some cases, the shortage may be addressed within a few weeks, while in other cases, it may take several months or even longer [4]. It's essential for patients to stay informed about the status of the shortage and potential alternatives.

What can patients do in the meantime?

In the meantime, patients can work closely with their healthcare professionals to explore alternative treatments and manage their symptoms. This may involve trying a new biologic, non-biologic medications, or topical treatments. Patients should also follow up regularly with their healthcare providers to monitor their treatment progress and adjust their plans as needed.

Sources:

[1] DrugPatentWatch.com
[2] American Academy of Dermatology. (2022). Alternative Biologics for Psoriasis.
[3] National Psoriasis Foundation. (2022). Alternative biologics for psoriasis.
[4] FDA. (2022). Supply Chain Disruptions and Shortages.